China Influenza Vaccine Market Size & Outlook, 2023-2030
China influenza vaccine market, 2018-2030 (US$M)
Related Markets
China influenza vaccine market highlights
- The China influenza vaccine market generated a revenue of USD 332.1 million in 2023 and is expected to reach USD 592.5 million by 2030.
- The China market is expected to grow at a CAGR of 8.6% from 2024 to 2030.
- In terms of segment, inactivated was the largest revenue generating vaccine type in 2023.
- Inactivated is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Influenza vaccine market data book summary
| Market revenue in 2023 | USD 332.1 million |
| Market revenue in 2030 | USD 592.5 million |
| Growth rate | 8.6% (CAGR from 2023 to 2030) |
| Largest segment | Inactivated |
| Fastest growing segment | Inactivated |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inactivated, Live Attenuated |
| Key market players worldwide | GSK PLC, Pfizer Inc, Merck & Co Inc, Viatris Inc, AstraZeneca PLC, Sinovac Biotech Ltd, CSL Ltd, Emergent BioSolutions Inc, Vaxess Technologies, Osivax, Emergex Vaccines |
Other key industry trends
- In terms of revenue, China accounted for 4.2% of the global influenza vaccine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China influenza vaccine market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 477.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Influenza Vaccine Market Scope
Influenza Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China influenza vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to influenza vaccine market will help companies and investors design strategic landscapes.
Inactivated was the largest segment with a revenue share of 91.57% in 2023. Horizon Databook has segmented the China influenza vaccine market based on inactivated, live attenuated covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the major pharmaceutical markets in APAC and its growth is driven by the local presence of a large number of vaccine manufacturers, favorable government initiatives, and high disease burden due to its large population. In addition, supportive regulatory framework and high demand for innovative vaccines are expected to offer lucrative growth opportunities in the market.
For instance, in May 2022, vaccine producer China National Biotec Group announced that its influenza vaccine, developed at its research center in Shanghai, was approved by the Chinese regulatory authorities. This newly approved vaccine can protect against COVID-19 and influenza strains.
In June 2020, Sinovac Biotech Ltd. announced that the NMPA issued a product license for its quadrivalent flu vaccine. The QIV vaccine contains two B strains & two A strains and can protect children older than 3 years from influenza.
Reasons to subscribe to China influenza vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China influenza vaccine market databook
-
Our clientele includes a mix of influenza vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China influenza vaccine market , including forecasts for subscribers. This country databook contains high-level insights into China influenza vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China influenza vaccine market size, by vaccine type, 2018-2030 (US$M)
China Influenza Vaccine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
